The Discovery of New Medicines in Academia, Volume 100 highlight examples of discoveries originating in academia that have been successfully translated into promising therapeutics that have advanced into clinical trials. Chapters in this release cover Design and Discovery of Itaconate prodrugs for Alopecia Areata, Hydroxyl-Dendrimer Delivery System for Neurological Disease, Development of allosteric modulators of G protein-coupled receptors for Psychiatric Disease, Targeting the constitutively active ERK1/2 signaling kinase for cancer, mRNA reprogramming of myeloid cells for tumor immunotherapy, Development of novel drugs targeting protein-protein interactions, and much more.
Additional sections cover Neuro-steroids and analogs for the treatment of epilepsy, Development of inhibitors of eukaryotic translation, Discovery/development of antiviral, anticancer and/or anti-inflammatory agents, Discovery of novel anti-infective agents, Targeting proliferating cell nuclear antigen (PCNA) for cancer, and Implementation and Evolution of Quantitative Systems Pharmacology to Patient Digital Twins and Biomimetic Twins.
1. Cover image - p. i 2. Title page - p. ii 3. Table of Contents - p. iii 4. Copyright - p. iii 5. Contributors - p. iii 6. Preface - p. iii 7. Chapter One: Making new drugs the hard way - p. 2 8. Chapter Two: Discovery of novel anti-infective agents - p. 40 9. Chapter Three: Journey from lab to clinic: Design, preclinical, and clinical development of systemic, targeted dendrimer-N-acetylcysteine (D-NAC) nanomedicines - p. 120 10. Chapter Four: Therapeutic resurgence of 6-diazo-5-oxo-L-norleucine (DON) through tissue-targeted prodrugs - p. 158 11. Chapter Five: Progress in the development of ERK1/2 inhibitors for treating cancer and other diseases - p. 182 12. Chapter Six: Targeting proliferating cell nuclear antigen (PCNA) for cancer therapy - p. 210 13. Chapter Seven: IVT-mRNA reprogramming of myeloid cells for cancer immunotherapy - p. 248
The Discovery of New Medicines in Academia, Volume 100 highlight examples of discoveries originating in academia that have been successfully translated into promising therapeutics that have advanced into clinical trials. Chapters in this release cover Design and Discovery of Itaconate prodrugs for Alopecia Areata, Hydroxyl-Dendrimer Delivery System for Neurological Disease, Development of allosteric modulators of G protein-coupled receptors for Psychiatric Disease, Targeting the constitutively active ERK1/2 signaling kinase for cancer, mRNA reprogramming of myeloid cells for tumor immunotherapy, Development of novel drugs targeting protein-protein interactions, and much more.
Additional sections cover Neuro-steroids and analogs for the treatment of epilepsy, Development of inhibitors of eukaryotic translation, Discovery/development of antiviral, anticancer and/or anti-inflammatory agents, Discovery of novel anti-infective agents, Targeting proliferating cell nuclear antigen (PCNA) for cancer, and Implementation and Evolution of Quantitative Systems Pharmacology to Patient Digital Twins and Biomimetic Twins.
1. Cover image - p. i 2. Title page - p. ii 3. Table of Contents - p. iii 4. Copyright - p. iii 5. Contributors - p. iii 6. Preface - p. iii 7. Chapter One: Making new drugs the hard way - p. 2 8. Chapter Two: Discovery of novel anti-infective agents - p. 40 9. Chapter Three: Journey from lab to clinic: Design, preclinical, and clinical development of systemic, targeted dendrimer-N-acetylcysteine (D-NAC) nanomedicines - p. 120 10. Chapter Four: Therapeutic resurgence of 6-diazo-5-oxo-L-norleucine (DON) through tissue-targeted prodrugs - p. 158 11. Chapter Five: Progress in the development of ERK1/2 inhibitors for treating cancer and other diseases - p. 182 12. Chapter Six: Targeting proliferating cell nuclear antigen (PCNA) for cancer therapy - p. 210 13. Chapter Seven: IVT-mRNA reprogramming of myeloid cells for cancer immunotherapy - p. 248
